Substituted indazole derivatives active as kinase inhibitors
US-9616059-B2 · Apr 11, 2017 · US
Substituted indazole derivatives active as kinase inhibitors
US10081622B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10081622-B2 |
| Application number | US-201715438872-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 22, 2017 |
| Priority date | Jul 20, 2007 |
| Publication date | Sep 25, 2018 |
| Grant date | Sep 25, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is 5-(3,5-difluorobenzyl)-2-fluoro-benzonitrile, having the structure 2. A method of preparing 5-(3,5-difluoro-benzyl)-1H-indazol-3-ylamine having the structure comprising allowing 5-(3,5-difluorobenzyl)-2-fluoro-benzonitrile to react with hydrazine. 3. A compound which is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-[(tetrahydropyran-4-yl)-(2,2,2-trifluoroacetyl)-amino]-benzamide, having the structure or a salt thereof. 4. A method of preparing N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydropyran-4-ylamino)-benzamide having the structure comprising allowing a compound which is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-[(tetrahydropyran-4-yl)-(2,2,2-trifluoroacetyl)-amino]-benzamide, having the structure or a salt thereof, to react with an aqueous solution of a base. 5. The method according to claim 4 , wherein said base is sodium hydrogencarbonate.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title
Free radical scavengers or antioxidants · CPC title
specific for metastasis · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10081622B2 cover?
- Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
- Who is the assignee on this patent?
- Nerviano Medical Sciences Srl
- What technology area does this patent fall under?
- Primary CPC classification C07D405/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).